prohibited list is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-16. Numbers and descriptions here follow the published literature rather than marketing material.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Thymosin beta-4 itself is a natural peptide of 43 residues found in many cell types and body fluids. Its best-characterised function is binding and sequestering actin monomers, which influences cytoskeletal dynamics. The sequence most often associated with TB-500, LKKTETQ, corresponds to part of that actin-binding region. A different fragment, Ac-SDKP, is also derived from the same parent peptide and is studied in its own right, which is one reason discussions of thymosin fragments can become confusing. The two are structurally distinct and are not interchangeable.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Name type | Commercial trade name | Not a systematic chemical identifier |
| Parent peptide | Thymosin beta-4 | 43-residue natural peptide |
| Common fragment sequence | LKKTETQ | Maps to part of the actin-binding region |
| Molecular size class | Roughly 0.8-1.0 kDa | Depends on exact fragment and terminal modification |
| Regulatory status | Prohibited in sport | Grouped with peptide hormones in many frameworks |
Material is normally supplied as a lyophilised powder in a sealed vial. The powder is hygroscopic, so exposure to humid air leads to water uptake, caking and gradual loss of the fluffy texture that indicates a good freeze-dry. Vials are best kept sealed with desiccant, protected from light and stored cold. Letting a cold vial warm to room temperature before opening reduces condensation on the contents. Purity is normally reported from a chromatographic run, and that figure applies to the batch as tested rather than to the vial after repeated opening.
Once dissolved, the peptide is far less stable than the dry powder. Aqueous solutions are subject to hydrolysis, oxidation at susceptible residues and gradual loss of material through adsorption onto glass and plastic surfaces. Terminal glutamine can cyclise under some conditions, producing a related species that complicates purity assessment. Dilute solutions tend to lose a larger fraction of material to surfaces than concentrated ones. Buffers, pH and ionic strength all influence the rate of change, so stability figures are only meaningful when those parameters are stated alongside the storage interval.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
== Safety == Ammonium bicarbonate is an irritant to the skin, eyes and respiratory system. Short-term health effects may occur immediately or shortly after exposure to ammonium bicarbonate. Breathing ammonium bicarbonate can irritate the nose, throat and lungs causing coughing, wheezing and/or shortness of breath. Repeated exposure may cause bronchitis to develop with cough, and/or shortness of breath. Health effects can occur some time after exposure to ammonium bicarbonate and can last for months or years. Where possible, operations should be enclosed and the use of local exhaust ventilation at the site of chemical release is recommended. If local exhaust ventilation or enclosure is not used, respirators are necessary. Wear protective work clothing and change clothes and wash thoroughly immediately after exposure to ammonium bicarbonate. Ammonium bicarbonate from China used to make cookies was found to be contaminated with melamine, and imports were banned in Malaysia following the 2008 Chinese milk scandal.
== Decline == Insulin coma therapy was used in most hospitals in the US and the UK during the 1940s and 1950s. The numbers of patients were restricted by the requirement for intensive medical and nursing supervision and the length of time it took to complete a course of treatment. For example, at one typical large British psychiatric hospital, Severalls Hospital in Essex, insulin coma treatment was given to 39 patients in 1956. In the same year, 18 patients received modified insulin treatment, while 432 patients were given electroconvulsive treatment. In 1953, British psychiatrist Harold Bourne published a paper entitled "The insulin myth" in the Lancet, in which he argued that there was no sound basis for believing that insulin coma therapy counteracted the schizophrenic process in a specific way. If treatment worked, he said, it was because patients were chosen for their good prognosis and were given special treatment: "insulin patients tend to be an elite group sharing common privileges and perils". Prior to publishing "The insulin myth" in The Lancet, Bourne had tried to submit the article to the Journal of Mental Science; after a 12-month delay, the Journal informed Bourne they had rejected the article, telling him to "get more experience". In 1957, when insulin coma treatment use was declining, The Lancet published the results of a randomized, controlled trial in which patients were either given insulin coma treatment or identical treatment but with unconsciousness produced by barbiturates.
They rapidly take up excess zinc through zinc transporters, shielding neurons from zinc toxicity. Astrocytes also participate in brain iron homeostasis by uptake via DMT1 and storage in ferritin. Dysregulation of astrocyte-mediated metal homeostasis is implicated in several neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Wilson's disease. Modulation of synaptic transmission: In the supraoptic nucleus of the hypothalamus, rapid changes in astrocyte morphology have been shown to affect heterosynaptic transmission between neurons. In the hippocampus, astrocytes suppress synaptic transmission by releasing ATP, which is hydrolyzed by ectonucleotidases to yield adenosine. Adenosine acts on neuronal adenosine receptors to inhibit synaptic transmission, thereby increasing the dynamic range available for LTP. Vasomodulation: Astrocytes may serve as intermediaries in neuronal regulation of blood flow. Promotion of the myelinating activity of oligodendrocytes: Electrical activity in neurons causes them to release ATP, which serves as an important stimulus for myelin to form. However, the ATP does not act directly on oligodendrocytes. Instead, it causes astrocytes to secrete cytokine leukemia inhibitory factor (LIF), a regulatory protein that promotes the myelinating activity of oligodendrocytes. This suggests that astrocytes have an executive-coordinating role in the brain. Nervous system repair: Upon injury to nerve cells within the central nervous system, astrocytes fill up the space to form a glial scar, and may contribute to neural repair.
Sources: en.wikipedia.org
This is because the amount of active enzyme at a given concentration of irreversible inhibitor will be different depending on how long the inhibitor is pre-incubated with the enzyme. Instead, kobs/[I] values are used, where kobs is the observed pseudo-first order rate of inactivation (obtained by plotting the log of % activity versus time) and [I] is the concentration of inhibitor. The kobs/[I] parameter is valid as long as the inhibitor does not saturate binding with the enzyme (in which case kobs = kinact) where kinact is the rate of inactivation.
Summarising their findings, they conclude: "The medical notes indicate that, on admission, Dylan's bronchial disease was found to be very extensive, affecting upper, mid and lower lung fields, both left and right." The forensic pathologist, Bernard Knight, who examined the post-mortem report, concurs: "death was clearly due to a severe lung infection with extensive advanced bronchopneumonia...the severity of the chest infection, with greyish consolidated areas of well-established pneumonia, suggests that it had started before admission to hospital." Thomas died at noon on 9 November 1953, having never recovered from his coma. A nurse, and the poet John Berryman, were present with him at the time of death.
== Women in Cinema Collective == In May 2017, following the sexual assault of a prominent Malayalam film actress in Kochi, Kallingal was among a group of women film professionals who petitioned the Chief Minister of Kerala and subsequently co-founded the Women in Cinema Collective (WCC). The WCC was formally registered as a society on 1 November 2017. The WCC's petition to the government resulted in the formation of the Justice Hema Committee in 2018, tasked with studying the conditions faced by women in the Malayalam film industry. The committee submitted its report in December 2019; it was made public in August 2024 and documented systemic issues including gender-based discrimination, inadequate workplace safety, and the prevalence of power-based exploitation. As a member of the Association of Malayalam Movie Artists (AMMA), Kallingal resigned in protest when the association reinstated a member accused in the 2017 assault case while the matter was still under judicial consideration. She was one of three WCC members — along with Geethu Mohandas and Remya Nambissan — to resign alongside the survivor herself. Kallingal has spoken publicly about the personal and professional costs of the collective's advocacy. "We knew it would be tough, but we never imagined it would cost us personal relationships, careers and expose us to such intense social trolling," she told The Federal in 2024.
Sources: en.wikipedia.org
Le Havre belongs to the Paris Basin which was formed in the Mesozoic period. The Paris Basin consists of sedimentary rocks. The commune of Le Havre consists of two areas separated by a natural cliff edge: one part in the lower part of the town to the south including the harbour, the city centre and the suburbs. It was built on former marshland and mudflats that were drained in the 16th century. The soil consists of several metres of alluvium or silt deposited by the Seine. The city centre was rebuilt after the Second World War using a metre of flattened rubble as a foundation. The upper town to the north, is part of the cauchois plateau: the neighbourhood of Dollemard is its highest point (between 90 and 115 metres (295 and 377 feet) above sea level). The plateau is covered with a layer of flinty clay and a fertile silt. The bedrock consists of a large thickness of chalk measuring up to 200 m (656 ft) deep. Because of the slope the coast is affected by the risk of landslides.
Transformation of a bacterial host with two different plasmids is required. One is designed to express a DNA-binding protein-of-interest as a fusion construct with a subunit of RNA polymerase (bait). The other plasmid contains a region of randomized sequence representing potential binding sites (prey) which, if bound to by the chimeric fusion product, drives expression of downstream reporter genes. This reporter region facilitates both positive and negative selection by HIS3 and URA3, respectively, which together allow for isolation of the prey containing the true DNA target sequence. HIS3 and URA3 encode proteins required for biosynthesis of histidine and uracil. Using a negative selectable marker is crucial for greatly reducing the incidence of false-positives. Self-activating prey, where the randomized region facilitate reporter expression in the absence of TF binding, are removed by transforming the reporter vector library into bacteria in the absence of bait and assaying for growth on plates containing 5-fluoro-orotic acid (5-FOA). The protein product of URA3 converts 5-FOA into a toxic compound, thereby allowing survival of only those colonies that contain reporter vectors which are not self-activating. Negative selection normally precedes positive selection so that a smaller, purified prey library can be subjected to the more rigorous positive selection process. Upon transformation of the purified prey library with the bait plasmid, positive selection is achieved by growing the host E.
PFAS are used in Class B firefighting foams due to their hydrophobic and lipophobic properties, as well as the stability of the chemicals when exposed to high heat. Though studies have been frequently limited by underpowered study designs, research indicates firefighters have higher blood levels of PFOS and PFHxS than the general population. PFAS exposure is prevalent among firefighters not only due to its use in emergencies but also because it is used in personal protective equipment. In support of these findings, states like Washington and Colorado have moved to restrict and penalize the use of Class B firefighting foam for firefighter training and testing. The September 11 attacks and resulting fires caused the release of toxic chemicals used in materials such as stain-resistant coatings. First responders to this incident were exposed to PFOA, PFNA, and PFHxS through inhalation of dust and smoke released during and after the collapse of the World Trade Center. First responders who were working at or near ground zero were assessed for respiratory and other health effects from exposure to emissions at the World Trade Center. Early clinical testing showed a high prevalence of respiratory health effects. Early symptoms of exposure often presented with persistent coughing and wheezing. PFOA and PFHxS levels were present in both smoke and dust exposure, but first responders exposed to smoke had higher concentrations of PFOA and PFHxS than those exposed to dust.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue natural peptide, while TB-500 is a commercial label applied to a short synthetic fragment of it. The two differ in length, sequence coverage and how they are handled in the laboratory.
Published work usually examines actin binding, cell migration and tissue repair endpoints in cell and animal models. Findings are generally described as preliminary, and controlled human data remain limited.
Because TB-500 is a trade name rather than a chemical identifier, different vendors and papers may attach it to different fragment lengths. Checking the stated sequence is the practical way to resolve the ambiguity.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.